Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
The SC formulation was approved under the brand name Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the United States. Year to date, Roche's shares have gained 8% compared with the industry's 25.4% growth. Image Source: Zacks Investment Research Roche's Tecentriq SC Approval Tecentriq Hybreza combines Tecentriq with Halozyme Therapeutics' Enhanze drug delivery technology. The FDA approval was based on data from the phase IB/III IMscin001 study. Data from the study showed comparable levels of Tecentriq in the blood, when administered subcutaneously, and a safety and efficacy profile consistent with the intravenous (IV) formulation. The mid-stage IMscin002 study showed that 71% of patients preferred Tecentriq Hybreza over IV infusion. The new SC option reduces treatment time to approximately seven minutes compared with 30-60 minutes for IV infus
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme cut to Neutral at J.P. Morgan on valuation [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $57.00 price target on the stock, up previously from $52.00.MarketBeat
- Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the FirmBusiness Wire
- FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech [Yahoo! Finance]Yahoo! Finance
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 8/6/24 - Beat
HALO
Sec Filings
- 9/26/24 - Form 4
- 9/26/24 - Form 144
- 9/25/24 - Form 144
- HALO's page on the SEC website